BILL ANALYSIS

HR4101

BULLISH

Cancer Drug Parity Act of 2025

HR4101 (Cancer Drug Parity Act of 2025) carries an AI-assessed market impact score of 4/10 with a bullish outlook for investors. This legislation directly affects Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK) and Bristol-Myers Squibb ($BMY) and 3 other tickers. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

4/10

Impact Score

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR4101 aims to equalize patient cost-sharing for oral and intravenously administered anticancer drugs.

The bill is in the early stages, having been referred to the House Committee on Education and Workforce.

If enacted, it would likely increase demand for oral anticancer medications by reducing patient out-of-pocket costs.

Pharmaceutical companies with strong oral oncology pipelines stand to benefit from increased patient access.

How HR4101 Affects the Market

The potential enactment of HR4101 presents a bullish outlook for pharmaceutical companies with substantial oral oncology portfolios. By mandating equal cost-sharing, the bill directly addresses a financial barrier that can limit patient access to these drugs. Companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Bristol Myers Squibb ($BMY), Amgen ($AMGN), Eli Lilly ($LLY), and Gilead Sciences ($GILD) are positioned to benefit from increased prescription volumes and revenue for their oral anticancer treatments. While the bill is in early stages, its progression would signal a more favorable market environment for these specific drug classes.

Bill Details

Metric	Value
Bill Number	HR4101
Impact Score	4/10Certainty: Introduced/Referred · Financial Magnitude: No explicit funding identified · Strategic Weight: AI qualitative assessment: 5/10 · Market Penetration: 7 companies — very broad impact
Market Sentiment	bullish
Event Date	June 24, 2025
Affected Sectors	Healthcare
Affected Stocks	Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Bristol-Myers Squibb ($BMY), Amgen ($AMGN), Eli Lilly ($LLY), Gilead Sciences ($GILD)
Source	View on Congress.gov →

Summary

HR4101, the Cancer Drug Parity Act of 2025, aims to equalize patient cost-sharing for oral and intravenously administered anticancer drugs. If enacted, this bill would reduce out-of-pocket costs for patients using oral anticancer medications, likely increasing demand for these treatments. Pharmaceutical companies with significant oral oncology portfolios stand to benefit from enhanced patient access.

Full AI Market Analysis

The Cancer Drug Parity Act of 2025 (HR4101) was introduced in the House on June 24, 2025, and subsequently referred to the House Committee on Education and Workforce. This bill is in the early stages of the legislative process. Its core objective is to amend the Employee Retirement Income Security Act of 1974 (ERISA) to mandate that group health plans provide cost-sharing for oral anticancer drugs on terms no less favorable than those for intravenously administered anticancer medications. This bill does not involve direct federal funding or appropriations. Instead, it operates through a regulatory mandate on private health insurance plans. The mechanism is a change to ERISA, which governs most private sector employee benefit plans. By requiring parity in cost-sharing, the bill aims to remove financial barriers for patients opting for oral anticancer treatments, which are often preferred for their convenience but can have higher out-of-pocket costs due to how they are classified by insurers compared to provider-administered drugs. Structural winners would be pharmaceutical companies that develop and market oral anticancer medications, as reduced patient costs are expected to drive increased demand and prescription volumes. Companies such as Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Bristol Myers Squibb ($BMY), Amgen ($AMGN), Eli Lilly ($LLY), and Gilead Sciences ($GILD) have significant oral oncology portfolios and would likely see a positive impact on their sales. Conversely, health insurance providers offering group health plans would be the obligated parties, potentially facing increased costs or adjustments to their benefit structures to comply with the parity requirement. The bill is currently in committee, indicating that it has a long legislative path ahead, including potential committee hearings, markups, and votes in both the House and Senate before it could be considered for presidential signature. There is no related presidential action that directly amplifies or conflicts with this specific bill's objective; the Executive Order on Accelerating Medical Treatments for Serious Mental Illness focuses on psychedelic-based therapies for mental health, a distinct area from cancer drug cost-sharing.